Skip to main content

Publications

 Foster H, Wilson C,  Philippou H, Foster R (2020). Progress toward a Glycoprotein VI Modulator for the Treatment of Thrombosis. J Med Chem, 63, 21, 12213–12242

Bartoli F, Bailey MA, Rode B, Mateo P, Antigny F, Bedouet K, Gerbaud P, Gosain R, Plante J, Norman K, Gomez S, Lefebvre F, Rucker-Martin C, Ainscough JFX, Kearney MT, Bruns A-F, Shi J, Appleby HL, Young RS, Shawer HM, Debant M, Gomez A-M, Beech DJ, Foster R,  Benitah J-P, Sabourin J (2020) Orai Channel Inhibition Preserves Left Ventricular Systolic Function and Normal Ca2+ Handling After Pressure Overload. Circulation, 141(3):199-216

Blythe NM, Muraki K, Ludlow MJ, Stylianidis V, Gilbert HTJ, Evans EL, Cuthbertson K, Foster R, Swift J, Li J, Drinkhill MJ, van Nieuwenhoven FA, Porter KE, Beech DJ, Turner NA (2019) Mechanically activated Piezo1 channels of cardiac fibroblasts stimulate p38 mitogen-activated protein kinase activity and interleukin-6 secretion

Duncan JA, Foster R, Kwok JCF (2019) The Potential of Memory Enhancement through Perineuronal Net Modulation. British Journal of Pharmacology, 176(18):3611-3621

Wetherill LF, Wasson CW, Swinscoe G, Kealy D, Foster R, Griffin S, Macdonald A (2018) Alkyl-Imino sugars inhibit the pro-oncogenic ion channel function of human papillomavirus (HPV) E5.  Antiviral Research, 158:113-121

Rubaiy HN, Ludlow MJ, Siems K, Norman K, Foster R, Wolf D, Beutler JA, Beech DJ (2018) Tonantzitlolone is a Nanomolar Potency Activator of TRPC1/4/5 Channels. British Journal of Pharmacology, 175 (16), 3361-3368

Evans EL, Cuthbertson K, Endesh N, Rode B, Blythe NM, Hyman AJ, Hall SJ, Gaunt HJ, Ludlow MJ, Foster R, Beech DJ (2018). Yoda1 analogue (Dooku1) which antagonizes Yoda1‐evoked activation of Piezo1 and aortic relaxation. British Journal of Pharmacology, 175(10), 1744-1759. doi:10.1111/bph.14188

Robinson JI, Baxter EW, Owen RL, Thomsen M, Tomlinson DC, Waterhouse MP, Win SJ, Nettleship JE, Tiede C, Foster RJ, Owens RJ, Fishwick CWG, Harris SA, Goldman A, McPherson MJ, Morgan AW. (2018). Affimer proteins inhibit immune complex binding to FcγRIIIa with high specificity through competitive and allosteric modes of action. Proceedings of the National Academy of Sciences, 115(1), E72-E81. doi:10.1073/pnas.1707856115

Ozsvari, B., Bonuccelli, G., Sanchez-Alvarez, R., Foster, R., Sotgia, F., & Lisanti, M. P. (2017). Targeting flavin-containing enzymes eliminates cancer stem cells (CSCs), by inhibiting mitochondrial respiration: Vitamin B2 (Riboflavin) in cancer therapy. Aging, 9(12), 2610-2628. doi:10.18632/aging.101351

Muraki K, Ohnishi K, Takezawa A, Suzuki H, Hatano N, Muraki Y, Hamzah N, Foster R, Waldmann H, Nussbaumer P, Christmann M, Bon RS, Beech DJ (2017). Na⁺ entry through heteromeric TRPC4/C1 channels mediates (-)Englerin A-induced cytotoxicity in synovial sarcoma cells. Scientific Reports, 7. doi:10.1038/s41598-017-17303-3

Rode B, Shi J, Endesh N, Drinkhill MJ, Webster PJ, Lotteau SJ, Bailey MA, Yuldasheva NY, Ludlow MJ, Cubbon RM, Li J, Futers TS, Morley L, Gaunt HJ, Marszalek K, Viswambharan H, Cuthbertson K, Baxter PD, Foster R, Sukumar P, Weightman A, Calaghan SC, Wheatcroft SB, Kearney MT, Beech DJ Piezo1 channels sense whole body physical activity to reset cardiovascular homeostasis and enhance performance Nature Communications 8 -, 2017
DOI:10.1038/s41467-017-00429-3

Ozsvari B, Fiorillo M, Bonuccelli G, Cappello AR, Frattaruolo L, Sotgia F, Trowbridge R, Foster R, Lisanti MP Mitoriboscins: Mitochondrial-based therapeutics targeting cancer stem cells (CSCs), bacteria and pathogenic yeast. Oncotarget 8 67457-67472, 2017
DOI:10.18632/oncotarget.19084

Man K, Jiang L-H, Foster R, Yang XB Immunological Responses to Total Hip Arthroplasty. Journal of Functional Biomaterials 8 -, 2017
DOI:10.3390/jfb8030033

Ozsvari B, Fiorillo M, Bonuccelli G, Cappello AR, Frattaruolo L, Sotgia F, Trowbridge R, Foster R, Lisanti MP Mitoriboscins: Mitochondrial-based therapeutics targeting cancer stem cells (CSCs), bacteria and pathogenic yeast Oncotarget 8 67457-67472, 2017
DOI:10.18632/oncotarget.19084

Rubaiy HN, Ludlow MJ, Henrot M, Gaunt HJ, Miteva K, Cheung SY, Tanahashi Y, Hamzah N, Musialowski KE, Blythe NM, Appleby HL, Bailey MA, McKeown L, Taylor R, Foster R, Waldmann H, Nussbaumer P, Christmann M, Bon RS, Muraki K, Beech DJ Picomolar, selective, and subtype-specific small-molecule inhibition of TRPC1/4/5 channels Journal of Biological Chemistry 292 8158-8173, 2017
DOI:10.1074/jbc.M116.773556

Bridge K, Revill C, Macrae F, Bailey M, Yuldasheva N, Wheatcroft S, Butlin R, Foster R, Scott DJ, Gils A, Ariëns R Inhibition of plasmin-mediated TAFI activation may affect development but not progression of abdominal aortic aneurysms PLoS ONE 12 -, 2017
DOI:10.1371/journal.pone.0177117

Ozsvari B, Sotgia F, Simmons K, Trowbridge R, Foster R, Lisanti MP Mitoketoscins: Novel mitochondrial inhibitors for targeting ketone metabolism in cancer stem cells (CSCs) Oncotarget 8 78340-78350, 2017
DOI:10.18632/oncotarget.21259

Schumann S, Jackson BR, Yule I, Whitehead SK, Revill C, Foster R, Whitehouse A Targeting the ATP-dependent formation of herpesvirus ribonucleoprotein particle assembly as an antiviral approach Nature Microbiology 2 -, 2016
DOI:10.1038/nmicrobiol.2016.201

Bailey MA, Rode B, Gosain R, Bridge KI, Griffin KJ, Shires M, Porter KE, Plein S, Wheatcroft SB, Foster R, Scott DJA, Beech DJ PATHOLOGICAL VASCULAR SMOOTH MUSCLE CELLS REMODELLING IN MURINE MODELS OF ABDOMINAL AORTIC ANEURYSM HEART 102 , 2016
DOI:10.1136/heartjnl-2016-310696.16

Read C, Fitzpatrick CM, Yang P, Kuc RE, Maguire JJ, Glen RC, Foster RE, Davenport AP Cardiac action of the first G protein biased small molecule apelin agonist Biochemical Pharmacology 116 63-72, 2016
DOI:10.1016/j.bcp.2016.07.018

Walter S, Bollenbach A, Doerrbecker J, Pfaender S, Brown RJP, Vieyres G, Scott C, Foster R, Kumar A, Zitzmann N, Griffin S, Penin F, Pietschmann T, Steinmann E Ion channel function and cross-species determinants in viral assembly of nonprimate hepacivirus p7 Journal of Virology 90 5075-5089, 2016
DOI:10.1128/JVI.00132-16

Young LM, Saunders JC, Mahood RA, Revill CH, Foster RJ, Ashcroft AE, Radford SE ESI-IMS-MS: A method for rapid analysis of protein aggregation and its inhibition by small molecules Methods 95 62-69, 2016
DOI:10.1016/j.ymeth.2015.05.017

Baxter EW, Robinson JI, Tomlinson DC, Foster RJ, Owen RL, Win SJ, Nettleship JE, Tiede C, Kankanala J, Owens RJ, Fishwick CWG, McPherson MJ, Morgan AW NOVEL AGENTS FOR BLOCKING THE INTERACTION OF IMMUNE COMPLEXES WITH THE ACTIVATORY FC gamma RIIIA RECEPTOR ANNALS OF THE RHEUMATIC DISEASES 75 , 2016
DOI:10.1136/annrheumdis-2016-209124.139

Saunders JC, Young LM, Mahood RA, Jackson MP, Revill CH, Foster RJ, Smith DA, Ashcroft AE, Brockwell DJ, Radford SE An in vivo platform for identifying inhibitors of protein aggregation Nature Chemical Biology 12 94-101, 2016
DOI:10.1038/nchembio.1988

Fisher MJ, Williamson DJ, Burslem GM, Plante JP, Manfield IW, Tiede C, Ault JR, Stockley PG, Plein S, Maqbool A, Tomlinson DC, Foster R, Warriner SL, Bon RS Trivalent Gd-DOTA reagents for modification of proteins RSC Advances 5 96194-96200, 2015
DOI:10.1039/c5ra20359g

Li J, Bruns A-F, Hou B, Rode B, Webster PJ, Bailey MA, Appleby HL, Moss NK, Ritchie JE, Yuldasheva NY, Tumova S, Quinney M, McKeown L, Taylor H, Prasad KR, Burke D, O'Regan D, Porter KE, Foster R, Kearney MT, Beech DJ Orai3 Surface Accumulation and Calcium Entry Evoked by Vascular Endothelial Growth Factor Arteriosclerosis, Thrombosis, and Vascular Biology 35 1987-1994, 2015
DOI:10.1161/ATVBAHA.115.305969

Firth JD, Zhang R, Morgentin R, Guilleux R, Kalliokoski T, Warriner S, Foster R, Marsden SP, Nelson A Exploitation of the Ugi-Joullié Reaction in the Synthesis of Libraries of Drug-Like Bicyclic Hydantoins Synthesis (Germany) 47 2391-2406, 2015
DOI:10.1055/s-0034-1378704

Wishart C, Hardy L, Corte ACL, Hethershaw E, Revill C, Fishwick C, Foster R, Ariens R, Philippou H surface plasmon resonance: SensiQ Pioneer as a means to screen drug discovery fragments for HITS JOURNAL OF THROMBOSIS AND HAEMOSTASIS 13 574-574, 2015

Bridge KI, Revill C, Bailey M, Yuldasheva N, Wheatcroft S, Butlin R, Foster R, Scott J, Gils A, Ariens R Inhibition of TAFI affects AAA formation and rupture in the angiotensin II model of abdominal aortic aneurysm JOURNAL OF THROMBOSIS AND HAEMOSTASIS 13 73-73, 2015

Colomer I, Adeniji O, Burslem GM, Craven P, Rasmussen MO, Willaume A, Kalliokoski T, Foster R, Marsden SP, Nelson A Aminomethylhydroxylation of alkenes: Exploitation in the synthesis of scaffolds for small molecule libraries Bioorganic and Medicinal Chemistry 23 2736-2740, 2015
DOI:10.1016/j.bmc.2015.01.058

Craven P, Aimon A, Dow M, Fleury-Bregeot N, Guilleux R, Morgentin R, Roche D, Kalliokoski T, Foster R, Marsden SP, Nelson A Design, synthesis and decoration of molecular scaffolds for exploitation in the production of alkaloid-like libraries Bioorganic and Medicinal Chemistry 23 2629-2635, 2015
DOI:10.1016/j.bmc.2014.12.048

Bailey MA, Rode B, Simpson CM, Green BL, Plante J, Foster R, Young R, Li J, Porter KE, Scott DJA, Beech DJ Functional significance of the novel CRAC channel inhibitor, JPIII in abdominal aortic aneurysm vascular smooth muscle cells BRITISH JOURNAL OF SURGERY 102 10-10, 2015

Bailey MA, Simpson CM, Green BL, Foster R, Porter KE, Scott DJA, Beech DJ Orai1 is a viable drug target in abdominal aortic aneurysm BRITISH JOURNAL OF SURGERY 102 12-12, 2015

Young LM, Saunders JC, Mahood RA, Revill CH, Foster RJ, Tu LH, Raleigh DP, Radford SE, Ashcroft AE Screening and classifying small-molecule inhibitors of amyloid formation using ion mobility spectrometry-mass spectrometry Nature Chemistry 7 73-81, 2015
DOI:10.1038/nchem.2129

Appleby H, Gaunt H, Jansz S, Hyman A, Stokes O, Young R, Foster R, Beech D Resistance of store-operated calcium entry to tumour microenvironment conditions and enhanced potency of Synta66 in colorectal adenocarcinoma cells FASEB JOURNAL 28 -, 2014

Bailey M, Young R, Rode B, Foster R, Li J, Beech D Significance of store operated calcium entry in human abdominal aortic aneurysm vascular smooth muscle cells FASEB JOURNAL 28 -, 2014

Foster TL, Thompson GS, Kalverda AP, Kankanala J, Bentham M, Wetherill LF, Thompson J, Barker AM, Clarke D, Noerenberg M, Pearson AR, Rowlands DJ, Homans SW, Harris M, Foster R, Griffin S Structure-guided design affirms inhibitors of hepatitis C virus p7 as a viable class of antivirals targeting virion release Hepatology 59 408-422, 2014
DOI:10.1002/hep.26685

Wetherill LF, Holmes K, Verow M, Muller M, Howell M, Harris M, Fishwick C, Stonehouse N, Foster R, Blair E, Griffin S, Macdonald A High-risk papillomavirus E5 oncoprotein displays channel-forming activity sensitive to small molecule inhibitors Journal of Virology 86 5341-5351, 2012
DOI:10.1128/JVI.06243-11

Li J, McKeown L, Ojelabi O, Stacey M, Foster R, O apos Regan D, Porter KE, Beech DJ Nanomolar potency and selectivity of a Ca 2+ release-activated Ca 2+ channel inhibitor against store-operated Ca 2+ entry and migration of vascular smooth muscle cells British Journal of Pharmacology 164 382-393, 2011
DOI:10.1111/j.1476-5381.2011.01368.x

Foster TL, Verow M, Wozniak AL, Bentham MJ, Thompson J, Atkins E, Weinman SA, Fishwick C, Foster R, Harris M, Griffin S Resistance mutations define specific antiviral effects for inhibitors of the hepatitis C virus p7 ion channel Hepatology 54 79-90, 2011
DOI:10.1002/hep.24371

Foster TL, Verow M, Wozniak M, Bentham M, Thompson J, Atkins E, Weinman S, Fishwick CWG, Foster RJ, Harris M, Griffin S Resistance mutations define specific antiviral effects for inhibitors of the hepatitis C virus (HCV) p7 ion channel Hepatology 54 79-90, 2011

Li J, McKeown L, Ojelabi O, Stacey M, Foster R, Porter K, Beech DJ Nanomolarpotency and selectivity of a CRAC channel blocker against store-operated Ca2+-entry and migration of vascular smooth muscle cells British Journal of Pharmacology 164 382-393, 2011

Li J, Cubbon R, Wilson L, Amer M, McKeown L, Hou B, Majeed Y, Tumova S, Semour V, Taylor H, Stacey M, Foster R, Porter K, Kearney M, Beech DJ Orai1 and CRAC channel dependence of VEGF-activated Ca2+-entry andendothelial tube formation Circulation Research 108 1190-1198, 2011

Stephens P, Hunter C, Bignell G, Edkins S, Davies H, Teague J, Stevens C, O'Meara S, Smith R, Parker A, Barthorpe A, Blow M, Brackenbury L, Butler A, Clarke O, Cole J, Dicks E, Dike A, Drozd A, Edwards K, Forbes S, Foster R, Gray K, Greenman C, Halliday K, Hills K, Kosmidou V, Lugg R, Menzies A, Perry J, Petty R, Raine K, Ratford L, Shepherd R, Small A, Stephens Y, Tofts C, Varian J, West S, Widaa S, Yates A, Brasseur F, Cooper CS, Flanagan AM, Knowles M, Leung SY, Louis DN, Looijenga LHJ, Malkowicz B, Pierotti MA, Teh B, Chenevix-Trench G, Weber BL, Yuen ST, Harris G, Goldstraw P, Nicholson AG, Futreal PA, Wooster R, Stratton MR, Canc Genome Project Collaborat Grp Intragenic ERBB2 kinase mutations in tumours NATURE 431 525-526, 2004
DOI:10.1038/431525b

Stephens P, Hunter C, Bignell G, Edkins S, Davies H, Teague J, Stevens C, O'Meara S, Smith R, Parker A, Barthorpe A, Blow M, Brackenbury L, Butler A, Clarke O, Cole J, Dicks E, Dike A, Drozd A, Edwards K, Forbes S, Foster R, Gray K, Greenman C, Halliday K, Hills K, Kosmidou V, Lugg R, Menzies A, Perry J, Petty R, Raine K, Ratford L, Shepherd R, Small A, Stephens Y, Tofts C, Varian J, West S, Widaa S, Yates A, Brasseur F, Cooper CS, Flanagan AM, Knowles M, Leung SY, Louis DN, Looijenga LHJ, Malkowicz B, Pierotti MA, Teh B, Chenevix-Trench G, Weber BL, Yuen ST, Harris G, Goldstraw P, Nicholson AG, Futreal PA, Wooster R, Stratton MR, Grp CGPC Intragenic ERBB2 kinase mutations in tumours NATURE 431 525-526, 2004
DOI:10.1038/431525b

Foster RJ, Carr RE, Fishwick CWG Cyclic-fused azomethine-, imidate-, and thioimidate methylides: An efficient regiocontrolled entry into spiro-fused pyrrolidines TETRAHEDRON LETT 37 5163-5166, 1996

Fishwick CWG, Foster RJ, Carr RE A short dipolar cycloaddition approach to gamma-lactam alkaloids from Cynometra hankei TETRAHEDRON LETT 37 3915-3918, 1996

Foster RJ, Carr RE, Fishwick CWG Hetero-1,3-dipolar cycloadditions of dithiolane-isocyanate iminium methylides: A novel route to 1,3-oxazolidine- and thiazolidine-2-thiones TETRAHEDRON LETT 37 711-714, 1996

Foster RJ, Carr RE, Fishwick CWG Dithiolane-isocyanate imminium methylides: A rapid stereoselective entry into gamma-lactams TETRAHEDRON LETT 36 9409-9412, 1995

Foster RJ Substituted imidazoheterocycle derivatives as cannabinoidreceptor modulators and their preparation, pharmaceutical compositions and use in the treatment of pain,

Foster RJ, Beckett P, Henault C, Rabolvsky J, Gauss J, Gustafson CM, Luo G, Cambell AM, Shelekhin T, Zablocki MM Preparation of substituted imidazoheterocycles, particularly 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazines and 6,7,8,9-tetrahydroimidazo[1,5-a][1,4]diazepines, as cannabinoid receptor modulators,

Foster RJ Substituted imidazoheterocycle derivatives as cannabinoid receptor modulators and their preparation, pharmaceutical compositions and use in the treatment of pain,

Foster R Kinase Inhibitors,

Foster R Kinase Inhibitors,

Foster R Preparation of Phenylpyrazoles as 5-HT2A Serotonin Receptor Modulators,

Foster R Sulfonamide-based Compounds as Protein Tyrosine Kinase Inhibitors,

Foster R Preparation of Thiazolylpiperidines as Microsomal Triglyceride Transfer Protein (MTP) and/or Apoprotein B (ApoB) Inhibitors Useful in the Treatment of Dyslipidemia and Related Diseases,

Foster R Preparation of Phenylpyrazoles as 5-HT2A Serotonin Receptor Modulators,

Foster R Substituted Azoles,

Foster R Partnering for Successful Informatics Driven Drug Discovery In Genetic Engineering News ,

Foster R Preparation of N-benzodioxolyl, N-benzodioxanyl, and N-benzodioxepinyl arylcarboxamides as Microsomal Triglyceride Transfer Protein (MTP) and/or Apoprotein B (ApoB) Inhibitors Useful in the Treatment of Dyslipidemia,

Foster R Kinase Inhibitors,

Foster R New Pyrazole Derivatives are 5-HT2A Inverse Agonists - Useful for the Treatment of CNS, Gastrointestinal, Cardiovascular and Inflammatory Disorders,

Foster R Kinase Inhibitors,

Foster RJ, Beckett P, Gauss C, Henault C, Gustaffson G Preparation of substituted imidazoheterocycles, particularly 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazines and 6,7,8,9-tetrahydroimidazo[1,5-a][1,4]diazepines, as cannabinoid receptor modulators,